Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24919549 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3CES2ARG1 | |
| SCHEMBL22625614 | 0.86 | NOS2 (0.42) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL19628285 | 0.84 | CYP2D6 (0.46) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL19628287 | 0.84 | CYP2D6 (0.46) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4992360 | 0.84 | NOS2 (0.53) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL19628286 | 0.84 | CYP2D6 (0.46) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4992347 | 0.84 | NOS2 (0.53) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL12421053 | 0.83 | NOS2 (0.36) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL15242542 | 0.79 | NOS2 (0.41) | NOS2NOS1NOS3CES2ARG1 | |
| SCHEMBL16572561 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638284-B1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-3077410-B1 | PROLINE-RICH PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE | VIROMETIX AG (CH) | 2021-02-03 | — | — | EP | disclosed |
| US-20160324947-A1 | PROLINE-RICH PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE | Universität Zürich (CH) | 2016-11-10 | — | — | US | disclosed |
| WO-2015082501-A1 | PROLINE-RICH PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE | VIROMETIX AG (CH) | 2015-06-11 | — | — | WO | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324947-A1 | PROLINE-RICH PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE | SGTA, PELP1, PRR12 | NOS2 3562/4885NOS1 3607/4885NOS3 2984/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | NOS2 2696/4885NOS1 3239/4885NOS3 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.